According to recent medical studies, one in every seven thousand childbirths is affected by lysosomal storage disease. This number is on the verge of increasing year by year, especially in underdeveloped countries where awareness and medical facilities regarding these diseases are found to be very scarce. This has created a conducive environment for the enzyme replacement therapy market with a staggering valuation of USD 10,707.6 million expected as of 2024.
ERT is also used in the treatment of various rare diseases such as Gaucher disease and Fabry disease. Advancements in medicare technology and the proliferation of modern and sophisticated facilities in healthcare organizations, both public as well as private, have further led to the expansion of this market. The industry is anticipated to grow at a healthy CAGR of 6.60% from 2024 to 2034.
Government initiatives to make people more aware and lenient reimbursement policies are also responsible for the growth of the market. The market is slated to reach a valuation of USD 20,289.1 million by the end of 2034.
However, increased costs and unavailability of skilled workforce and healthcare facilities are hindering market growth in some parts of the world. Coupled with a lack of awareness and concerns regarding the efficacy of these treatments, the market has definite obstacles to face in the forecast period.
| Attributes | Details |
|---|---|
| Market Value for 2024 | USD 10,707.6 million |
| Projected Market Value for 2034 | USD 20,289.1 million |
| Value-based CAGR of the Market for 2024 to 2034 | 6.60% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
ERT is used to treat various rare diseases such as Fabry Disease, Gaucher Disease, Mucopolysaccharidosis, etc. Among these, the Mucopolysaccharidosis segment is estimated to hold the largest market share of 24.10% in 2024.
| Attributes | Details |
|---|---|
| Therapeutic Condition | Mucopolysaccharidosis |
| Market Share (2024) | 24.10% |
ERTs can be administered through two major routes which are oral and injectable. Among these, the injectable ERT is predicted to hold a market share of 86.90% in 2024.
| Attributes | Details |
|---|---|
| Route of Administration | Injectable |
| Market Share (2024) | 86.90% |
| Countries | CAGR (2024 to 2034) |
|---|---|
| Japan | 8.00% |
| China | 7.30% |
| Canada | 6.90% |
| Australia and New Zealand | 6.30% |
| Brazil | 6.00% |
The enzyme replacement therapy market in Japan is a promising one. It is slated to grow at a CAGR of 8.00% through 2034.
Japan is currently dealing with a growing aging population. As of 2024, one in every four people living in Japan is above the age of sixty. This has created a conducive environment for ERTs as this demographic is more susceptible to rare diseases.
Responding to these demands, Japanese healthcare companies are also investing billions of dollars in curating novel technologies and therapies to tackle these fatal diseases. For instance, in March 2022, Sanofi's Xenpozyme gained approval in Japan, marking a historic milestone as the inaugural treatment for ASMD.
China is a lucrative country in this market. The enzyme replacement therapy market is inclined to grow at a CAGR of 7.30% through 2034 in the country.
The Chinese government, in the last few years, has been announcing a multitude of schemes and policies to strengthen its medical infrastructure. The recent pandemic has also put a lot of pressure on the Chinese healthcare sector.
All these factors have led to the adoption of best-in-class medical facilities in the country. This improved medical infrastructure has led to the expansion of the ERT market as more people become aware of rare diseases for which this treatment is used.
The future of the Canada ERT market also looks very bright. The market is slated to grow at a CAGR of 6.90% through 2034 in Canada.
The presence of numerous medical institutes and government support in the form of grants and subsidies to the same have proved to be a boon for Canada’s healthcare sector. This has also benefitted ERTs as medicare research institutes have come up with top-tier methodologies for treating deadly diseases in the country.
The Australia and New Zealand ERT market is slated to grow at a CAGR of 6.30% from 2024 to 2034.
Although the incidence of LSDs in Australia and New Zealand is very scarce, both countries are conducting continuous research and development in these fields. The purpose is to entirely terminate these diseases from their population.
Players involved in the ERT market are pouring billions of dollars into making therapies affordable for the common public. For instance, in April 2024, Inozyme Pharma initiated the Phase Ib ENERGY-1 trial, dosing the first infant with INZ-701 enzyme therapy for ENPP1 deficiency, aiming to assess safety and efficacy.
The market in Brazil is very likely to flourish in the coming years. It is slated to grow at a CAGR of 6.00% through 2034.
Lysosomal storage disorders are gradually picking up pace in Brazil. To mitigate these diseases altogether Brazilian companies are collaborating with international partners. They are also investing in research and developing innovative therapies to address lysosomal storage disorders in the country.
The enzyme replacement therapy market is a very limited one as the disease mortality rate is minuscule. This is why very few companies exist in the market, most of which have already established themselves as key players.
The competition is also not that intense as top players hold the majority share of the market. Besides this, these companies are found collaborating with research institutions for more effective and affordable therapies.
Recent Developments in the Enzyme Replacement Therapy Market:
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The market is expected to be worth USD 10,707.6 million in 2024.
The enzyme replacement therapy market is expected to reach USD 20,289.1 million by 2034.
The market is in line to grow at a CAGR of 6.60% from 2024 to 2034.
BioMarin Pharmaceutical Inc., Amicus Therapeutics, Sanofi Genzyme, Alexion Pharmaceuticals, and Ultragenyx Pharmaceutical Inc., are some of the major players in the market.
The market valuation in 2023 was USD 10,011.1 million.
| Estimated Market Size, 2024 | USD 16,825.2 million |
|---|---|
| Expected Market Share, 2034 | USD 23,729.6 million |
| Value CAGR (2024 to 2034) | 3.50% |
| Expected Market Value in 2023 | USD 4.2 Billion |
|---|---|
| Projected Market Value in 2033 | USD 7.4 Billion |
| Growth Rate (2023 to 2033) | CAGR of 5.8% |
Explore Therapy Area Insights
View Reports
Enzyme Replacement Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
